This review shows how glycosylation modifies EGFR, impacting cancer malignancy in cells, suggesting potential therapeutic targets.
Glycosylation is involved in the pathogenesis of various diseases and also plays an important role in the acquisition of malignant properties by cancers. Epidermal growth factor receptor (EGFR) promotes the malignant properties of various cancers, and its activity is enhanced by its overexpression or gene mutations. EGFR is modified by glycosylation, which regulates its activity and the affinity of EGF–EGFR binding. In this review, we introduce the effects of glycans attached to EGFR on the acquisition of malignant properties by cancer cells, including head and neck squamous cell carcinomas.
No takes yet. Share an insight, caveat, or question.
Hamamura et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: